Evaxion's CMV Vaccine EVX-V1 Demonstrates Improved Infection Control in New Preclinical Data
EVAX sits 32% above its 52-week low of $2.45 on light trading volume (0.3× avg).
Summary
Evaxion's EVX-V1 CMV vaccine candidate demonstrated improved control of acute infection, latency, and reactivation in preclinical models, supporting its multi-component AI-designed approach.
Key Events · Product Development and Regulatory · EVAX
-
New Preclinical Data for EVX-V1
AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice, complementing prior B-cell antigen data.
-
Multi-Component Vaccine Strategy
EVX-V1 combines novel AI-discovered antigens with optimized established antigens, targeting CMV from multiple angles to enhance protective potential.
-
Presentation at IHW 2026
Data was presented in a poster session at the International Herpesvirus Workshop 2026 in Montreal, Canada, on July 12, 2026.
-
Unmet Medical Need
No CMV vaccine is approved despite decades of research; CMV causes severe disease in immunocompromised individuals and infants, with a treatment market valued at $474.6M in 2023.
Analysis · EVAX · Life Sciences
At the International Herpesvirus Workshop 2026, Evaxion presented new preclinical data for its CMV vaccine candidate EVX-V1. The results show that AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. This builds on prior findings of reduced viral infection from novel B-cell antigens and superior neutralization from optimized structural antigens. The multi-component approach strengthens the vaccine's protective potential, addressing a market with no approved vaccine and significant unmet need. For a company with a market cap around $26 million, positive preclinical data for a major indication like CMV is a notable step forward, though still early-stage.
How filings like this one have moved
In the 30 days to Sep 18, 2026, 29.3% of the 1681 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.4M. The 52-week trading range was $2.45 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.